CAS: 30286-75-0; Tersigat

上下游产品

CAS号74-96-4 溴乙烷 | CAS号74-83-9 溴甲烷 | CAS号67009-40-9 (-)-N-Ethylnors... | CAS号114-49-8 氢溴酸东莨菪碱 | CAS号24676-80-0 Norscopolamine ... | CAS号67009-40-9 (-)-N-Ethylnors... | CAS号51-34-3 东莨菪碱

东莨菪碱氢溴酸盐 在 盐酸,Potassium Permanganate,硫酸,Sodium Carbonate体系中,用 乙腈作为反应溶剂,反应 78.0H,获得 Tersigat
参考文献:Banholzer; Pook,Arzneimittel-Forschung/Drug Research,1985,Vol. 35,# 1 A,P. 217-228
标题:Banholzer; Pook,Arzneimittel-Forschung/Drug Research,1985,Vol. 35,# 1 A,P. 217-228

专利信息

专利号:US-2006167025-A1
优先权日:2004-12-22
标 题:Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
发明人：BERGER MARKUS; SCHMEES NORBERT; SCHAECKE HEIKE; BAURLE STEFAN; REHWINKEL HARTMUT; MENGEL ANNE; KROLIKIEWICZ KONRAD; GROSSBACH DANJA; VOIGTLAENDER DAVID
权利人:BERGER MARKUS; SCHMEES NORBERT; SCHAECKE HEIKE; BAURLE STEFAN; REHWINKEL HARTMUT; MENGEL ANNE; KROLIKIEWICZ KONRAD; GROSSBACH DANJA; VOIGTLAENDER DAVID
摘要:The invention relates to tricyclic amino alcohols of general formula (I) n nmethod for synthesis of same and use of same as anti-inflammatory agents.

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-5900227-A
优先权日:1996-06-17
标题 :Multicyclic nitrone spin trapping compositions
发明人：JANZEN EDWARD G; SANKURATRI NAGARAJU
权利人:OKLAHOMA MED RES FOUND
摘要:Multicyclic nitrone spin trapping compounds capable of forming stable free radical spin adducts are provided as well as methods for their synthesis. The multicyclic nitrone spin trapping compounds can be reacted with a free radical, such as a hydroxy or hydroperoxy radical, in solution to form a spin adduct which is stable and readily detectable by electron paramagnetic resonance (EPR) spectroscopy. The multicyclic nitrone spin traps can be used to detect free radicals in a sample such as a biological system. In one embodiment, the spin trapping compound, 1,3,3-trimethyl-6-azabicyclo-[3.2.1]oct-6-ene-N-oxide ('TRAZON') is provided, as well as methods for the synthesis of TRAZON and of modified forms of TRAZON. TRAZON can react with a wide range of different free radicals in solution to form free radical spin adducts which are readily detectable by EPR.

专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-2006228305-A1
优先权日:2003-02-11
标题 :Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
发明人：MEADE CHRISTOPHER J M; PIEPER MICHAEL P; PAIRET MICHEL
权利人:BOEHRINGER INGELHEIM INT
摘要:The present invention relates to novel pharmaceutical compositions based on anticholinergics and TNF-alpha-antagonists, processes for preparing them and their use in the treatment of respiratory diseases.

专利号:US-10308615-B2
优先权日:2015-05-29
标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.